<DOC>
	<DOC>NCT00494481</DOC>
	<brief_summary>To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology</brief_summary>
	<brief_title>E3 Breast Cancer Taxotere Combination</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Females with histological/cytological confirmation of breast cancer. Subjects with a measurable lesion or bone lesions Previous radiotherapy within 6 weeks Significant cardiac events, arrhythmias or other cardiac conditions</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Zactima</keyword>
</DOC>